study of an experimental drug or combination of drugs to treat castration resistant metastatic prostate cancer

What we are studying

subjects with prostate cancer that has spread and has not responded to hormonal therapy will be randomized to receive either enzalutamide alone or enzalutamide, abiraterone and prednisone

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18 - 90

Eligibility Criteria

  • Subjects must be able to swallow pills

What is involved

  • Study participants in Arm A will take enzalutamide in 28-day cycles as long as their cancer is responding to treatment Study participants in Arm B will take enzalutamide with or without abiraterone and prednisone in 28-day cycles as long as their cancer is responding to treatment

Contact Information

Study Coordinator
Patricia Smith
Email
psmith@wakehealth.edu
Phone
336-713-4416

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.